Drug Price Transparency Act

Bill: 115-hr-6958
Sponsor: full_name: Rep. Rooney, Francis [R-FL-19]
Introduced: 2018-09-27
Policy area: Health
Subjects: Congressional oversight

Government studies and investigations

Health care costs and insurance

Inflation and prices

International organizations and cooperation

Medicare

Prescription drugs
Latest action: action_date: 2018-10-10
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2018-09-27
action_desc: Introduced in House
text: <p><b>Drug Price Transparency Act</b></p> <p>This bill requires the Centers for Medicare &amp; Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development). </p>

tv_txt: I 115th CONGRESS 2d Session H. R. 6958 IN THE HOUSE OF REPRESENTATIVES September 27, 2018 Mr. Francis Rooney of Florida (for himself and Mr. Welch ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.

1. Short title This Act may be cited as the Drug Price Transparency Act . 2. Study and report on feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on average prices for such drugs in OECD member states From amounts otherwise made available to the Secretary of Health and Human Services, the Secretary shall use not to exceed $100,000 of such amounts to, not later than 90 days after the date of the enactment of this Act, conduct a study, and submit to Congress a report, on the feasibility of— (1) basing reimbursement rates under part B of the Medicare program under title XVIII of the Social Security Act for prescription drugs for which coverage is provided under part B of the Medicare program on the average price of such drugs in the member-states of the Organization for Economic Cooperation and Development; and (2) basing payment rates under prescription drug plans under part D of such title (and under MA–PD plans under part C of such title) for covered part D drugs (as defined in section 1860D–2(e) of such Act ( 42 U.S.C. 1395w–102(e) )) on the average price of such drugs in such member-states.